Molecular mechanisms of medullary thyroid carcinoma: Current approaches in diagnosis and treatment

Histology and Histopathology

Volumn 23, Issue 1, 2008, Pages 109-116

  Boikos, S A ^a   Stratakis, Constantine A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Medullary thyroid cancer; Multiple endocrine neoplasia type 22; RET oncogene; Tyrosine kinase inhibitors

Indexed keywords

PROTEIN RET; RET PROTEIN, HUMAN; UNCLASSIFIED DRUG;

GENETICS; HUMAN; MEDULLARY CARCINOMA; MUTATION; PHYSIOLOGY; PROGNOSIS; REVIEW; SIPPLE SYNDROME; THYROID TUMOR; THYROIDECTOMY;

CARCINOMA, MEDULLARY; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 35748944138     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Angrist M., Bolk S., Hallushka M., Lapchak P.A. and Chakravarti A. (1996). Germline mutations in glial-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nat. Genet. 14, 341-344.
2. Asari R., Scheuba C., Kaczirek K. and Niederle B. (2006). Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch. Surg. 141, 1199-205.
3. Bethanis S., Koutsodontis G., Palouka T., Avgoustis C., Yannoukakos D., Bei T., Papadopoulos S. Linos D. and Tsagarakis S. (2007). A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones (Athens). 6, 152-156.
4. Blaugrund J.E., Johns M.M., Eby Y.J., Ball D.W., Baylin SB., Hruban R.H. and Sidransky D. (1994). RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum. Mol. Genet. 3, 1895-1897.
5. Borrego S., Eng C., Sanchez B., Saez M.E., Navarro E. and Antinolo G. (1998). Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J. Clin. Endocrinol. Metab. 83, 3361-3364.
6. Cameron J.L. (2004). Current surgical therapy. Philadelphia: Elsevier Mosby.
7. Carlomagno F., Vitagliano D., Guida T., Ciardiello F., Tortora G., Vecchio G., Ryan AJ., Fontanini G., Fusco A. and Santoro M. (2002a). ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62, 7284-7290.
8. Carlomagno F., Vitagliano D., Guida T., Napolitano M., Vecchio G., Fusco A., Gazit A., Levitzki A. and Santoro M. (2002b). The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res. 62, 1077-1082.
9. Carlomagno F., Vitagliano D., Guida T., Basolo F., Castellone MD., Melillo RM., Fusco A. and Santoro M. (2003). Efficient inhibition of RET/ papillary thyroid carcinoma oncogenic kinases by 4-amino-5- 2 - (4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4- d]pyrimidine (PP2). J. Clin. Endocrinol. Metab. 88, 1897-1902.
10. Carlomagno F., Anaganti S., Guida T., Salvatore G., Troncone G., Wilhelm S.M. and Santoro M. (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98, 326-334.
11. Cerchia L., Libri D., Carlomagno M.S. and de Franciscis V. (2003). The soluble ectodomain of RETC634Y inhibits both the wild-type and the constitutively activated RET. Biochem. J. 372, 897-903.
12. Cerchia L., Duconge F., Pestourie C., Boulay J., Aissouni Y., Gombert K., Tavitian B., de Franciscis V. and Libri D. (2005). Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PloS Biol. 3, e123.
13. Clayman G.L. and el-Baradie T.S. (2003). Medullary thyroid cancer. Otolaryngol. Clin. North. Am. 36, 91-105.
14. Cohen M.S., Hussain H.B. and Moley J.F. (2002). Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132, 960-967.
15. Cranston A.N., Carniti C., Oakhill K., Radzio-Andzelm E., Stone E.A., McCallion A.S., Hodgson S., Clarke S., Mondellini P., Leyland J., Pierotti M.A., Whittaker J., Taylor S.S., Bongarzone I. and Ponder B.A. (2006). RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.Cancer Res. 66, 10179-10187.
16. Cuccuru G., Lanzi C., Cassinelli G., Pratesi G., Tortoreto M., Petrangolini G., Seregni E., Martinetti A., Laccabue D., Zanchi C. and Zunino F. (2004). Cellular effects and antitumor activity of the RET inhibitor RPI-1 on MEN2Aassociated medullary thyroid carcinoma. J. Natl. Cancer Inst. 96, 1006-1014.
17. D'Aloiso L., Carlomagno F., Bisceglia M., Anaganti S., Ferretti E., Verrienti A., Arturi F., Scarpelli D., Russo D., Santoro M. and Filetti S. (2006). Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 91, 754-759.
18. Decker R.A., Peacock M.L. and Watson P. (1998). Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum. Mol. Genet. 7, 129-134.
19. Dvorakova S., Vaclavikova E., Duskova J., Vlcek P., Ryska A. and Bendlova B. (2005). Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J. Endocrinol. Invest. 28, 905-909.
20. Elisei R., Cosci B., Romei C., Bottici V., Sculli M., Lari R., Barale R., Pacini F. and Pinchera A. (2004). RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J. Clin. Endocrinol. Metab. 89, 3579-3584.
21. Eng C. (1996). The RET proto-oncogene in Multiple Endocrine Neoplasia type 2 and Hirschprung's disease. N. Engl. J. Med. 335, 943-951.
22. Eng C., Mulligan L.M., Smith D.P., Healey C.S., Frilling A., Raue F., Neumann H.P.H., Pfragner R., Behemel A., Lorenzo M.J., Stonehouse T.J., Ponder M.A. and Ponder B.A.J. (1995). Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12, 209-212.
23. Eng C., Clayton D., Schuffenecker I., Lenoir G., Cote G., Gagel R.F., van Amstel H.K., Lips C.J., Nishisho I., Takai S.I., Marsh D.J., Robinson B.G., Frank-Raue K., Raue F., Xue F., Noll W.W., Romei C., Pacini F., Fink M., Niederle B., Zedenius J., Nordenskjold M., Komminoth P., Hendy G.N. and Mulligan L.M. (1996). The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276,1575-1579.
24. Eng C. and Mulligan L.M. (1997). Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum. Mutat. 9, 97-109.
25. Evans D.B., Shapiro S.E. and Cote G.J. (2007). Invited commentary: medullary thyroid cancer: the importance of RET testing. Surgery 141, 96-99.
26. Ezzat S., Huang P., Dackiw A. and Asa S.L. (2005). Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin. Cancer Res. 11, 1336-1341.
27. Farndon J.R., Leight G.S., Dilley W.G., Baylin S.B., Smallridge R.C., Harrison T.S. and Wells S.A. Jr (1986). Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br. J. Surg. 73, 278-281.
28. Fialkowski E.A. and Moley J.F. (2006). Current approaches to medullary thyroid carcinoma, sporadic and familial. J. Surg. Oncol. 94, 737-747.
29. Fryns J.P. and Chrzanowska K. (1988). Mucosal neuromata syndrome (MEN type IIb (III)). J. Med. Genet. 25, 703-706.
30. Gagel R.F., Levy M.L., Donovan D.T., Alford B.R., Wheeler T. and Tchen J.A. (1989). Multiple endocrine neoplasia type 2A associated with cutaneous lichen amyloidosis. Ann. Intern. Med. 111, 802-806.
31. Gharib H., McConahey W.M., Tiegs R.D., Bergstralh E.J., Goellner J.R., Grant C.S., van Heerden J.A., Sizemore G.W. Hay I.D. (1992). Medullary thyroid carcinoma: clinicopathologic features and long term follow-up of 65 patients treated during 1946-1970. Mayo Clin. Proc. 67, 934-940.
32. Grisieri P., Sancandi M., Patrone G., Bocciardi R., Hofstra R., Ravazzolo R., Devoto M., Romeo G. and Ceccherini I. (2000). A single nucleotide polymorphic variant of the RET proto-oncogene is underrepresented in sporadic Hirschsprung disease. Eur. J. Hum. Genet. 8, 721-724.
33. Guillem J.G., Wood W.C., Moley J.F., Berchuck A., Karlan B.Y., Mutch D.G., Gagel R.F., Weitzel J., Morrow M., Weber B.L., Giardiello F., Rodriguez-Bigas M.A., Church J., Gruber S. and Offit K.; ASCO; SSO. (2006). ASCO/SSO review of current role of risk reducing surgery in common hereditary cancer syndromes. J. Clin. Oncol. 24, 4642-4660.
34. Gulben K., Berberoglu U. and Boyabatli M. (2006). Prognostic factors for sporadic medullary thyroid carcinoma. World J. Surg. 30, 84-90.
35. Hazard J., Hawk W. and Crile D. (1959). Medullary (solid) carcinoma of the thyroid - a clinicopathologic entity. J. Clin. Endocrinol. Metab. 19, 152-161.
36. Herfarth K.K., Bartsch D., Doherty G.M., Wells S.A. Jr. and Lairmore T.C. (1996). Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 120, 966-973.
37. Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Steelwagwn T., Luo Y., Pasini B., Hoppner J.W.M., Ploosvanamstel HK., Romeo G., Lips C. and Buys C. (1994). A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367, 375-376.
38. Huang S.C., Koch C.A., Vortmeyer A.O., Pack S.D., Lichtenauer U.D., Mannan P., Lubensky I.A., Chrousos G.P., Gagel R.F., Pacak K. and Zhuang Z. (2000). Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res. 60, 6223-6266.
39. Huang S.C., Torres-Cruz J., Pack S.D., Koch C.A., Vortmeyer A.O., Mannan P., Lubensky I.A., Gagel R.F. and Zhuang Z. (2003). Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 88, 459-463.
40. Kebebew E., Ituarte P.H., Siperstein A.E., Duh Q.Y. and Clark O.H. (2000). Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88, 1139-48.
41. Lakhani V.T., You Y.N. and Wells S.A. (2007). The multiple endocrine neoplasia syndromes. Annu. Rev. Med. 58, 253-265.
42. Lenders J.W., Eisenhofer G., Mannelli M. and Pacak K. (2005). Phaeochromocytoma. Lancet 366, 665-675.
43. Marsh D.J., Learoyd D.L., Andrew S.D., Krishnan L., Pojer R., Richardson A.L., Delbridge L., Eng C. and Robinson B.G. (1996). Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin. Endocrinol. (Oxf) 44, 249-257.
44. Morrison P.J. and Nevin N.C. (1996). Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome). J. Med. Genet. 33, 779-782.
45. Mulligan L.M., Gardner E., Smith B.A., Mathew C.G.P. and Ponder B.A.J. (1993). Genetic events in tumor initiation and progression in multiple endocrine neoplasia type 2. Genes Chromosomes Cancer 6, 166-177.
46. Ogilvie J.B. and Kebebew E. (2006). Indication and timing of thyroid surgery for patients with hereditary medullary thyroid cancer syndromes. J. Natl. Compr. Canc. Netw. 4, 139-147.
47. Peixoto Callejo I., Americo Brito J., Zagalo C.M. and Rosa Santos J. (2006). Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival. Clin. Transl. Oncol. 8, 435-443.
48. Ponder B.A.J. (1999). The phenotypes associated with RET mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res. 59, 1736-1742.
49. Prazeres H.J., Rodrigues F., Figueiredo P., Naidenov P., Soares P., Bugalho M.J., Lacerda M., Campos B. and Martins T.C. (2006). Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Clin. Endocrinol. (Oxf). 64, 659-666.
50. Romei C., Elisei R., Pinchera A., Ceccherini I., Molinaro E., Mancusi F., Martino E., Romeo G. and Pacini F. (1996). Somatic mutations of the RET protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon16 and are associated with tumor recurrence. J. Clin. Endocrinol. Metab. 81, 1619-1622.
51. Ruiz A., Antinolo G., Fernandez R.M., Eng C., Marcos I. and Borrego S. (2001). Germline sequence variant S836S in the RET protooncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin. Endocrinol. (Oxf) 55, 399-402.
52. Schimke R.N. and Hartmann W.H. (1965). Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma, a distinct genetic entity. Ann. Intern. Med. 63, 1027-1039.
53. Sherman S.I., Angelos P., Ball D.W., Beenken S.W., Byrd D., Clark O.H., Daniels G.H., Dilawari R.A., Ehya H., Farrar W.B., Gagel R.F., Kandeel F., Kloos R.T., Kopp P., Lamonica D.M., Loree T.R., Lydiatt W.M., McCaffrey J., Olson J.A Jr., Ridge J.A., Robbins R., Shah J.P., Sisson J.C. and Thompson N.W. (2005). National Comprehensive Cancer Network. Thyroid carcinoma. J. Natl. Compr. Canc. Netw. 3, 404-457.
54. Sipple J.H. (1961). The association of pheochromocytoma with carcinoma of the thyroid gland. Am. J. Med. 31, 163-166.
55. Skinner M.A., Moley J.A., Dilley W.G., Owzar K., DeBenedetti M.K. and Wells S.A. Jr (2005). Prophylactic thyroidectomy in multiple endocrine neoplasia Type 2A. N. Engl. J. Med. 353, 1105-1113.
56. Steiner A.L., Goodman A.D. and Powers S.R. Jr. (1968). Study of kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type II. Medicine 47, 371-409.
57. Strock C.J., Park J.I., Rosen M., Dionne C., Ruggeri B., Jones-Bolin S., Denmeade S.R., Ball D.W. and Nelkin B.D. (2003). CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 63, 5559-5563.
58. Strock C.J., Park J.I., Rosen D.M., Ruggeri B., Denmeade S.R., Ball D.W. and Nelkin B.D. (2006). Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J. Clin. Endocrinol. Metab. 91, 79-84.
59. Vidal M., Wells S., Ryan A. and Cagan R. (2005). ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 65, 3538-3541.
60. Vierhapper H., Rondot S., Schulze E., Wagner L., Hanslik S., Niederle B., Bieglmayer C., Kaserer K. and Baumgartner-Parzer S. (2005). Primary hyperparathyroidism as the leading symptom in a patient with a Y791F RET mutation. Thyroid 11, 1303-8.
61. Wermer P. (1954). Genetic aspects of adenomatosis of endocrine glands. Am. J. Med. 16, 363-371.
62. Williams E.D. and Pollock D.J. (1966). Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen's disease. J. Path. Bact. 91, 71-80.
63. Wohllk N., Cote G.J., Bugalho M.M., Ordonez N., Evans D.B., Goepfert H., Khorana K.S., Schultz P., Richards C.S. and Gagel R.F (1996). Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 81, 3740-3745.
64. Zedenius J., Walljn G., Hamberger B., Nordenskjold M., Weber G. and Larsson C. (1994). Somatic and MEN2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum. Mol. Genet. 3, 1259-1262.
65. Zelinka T., Pacak K. and Widimsky J. Jr. (2006). Characteristics of blood pressure in pheochromocytoma. Ann. NY Acad. Sci. 1073, 86-93.